Back

Effect of empagliflozin on epicardial adipose tissue volume in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)

1 September 2024 (10:00 - 10:50)
Organised by: Logo
Congress Presentation Part of: Obesity and heart failure: what's new? Imaging ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Ms Ceren Turgut

Glasgow (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
In-hospital economic impact and mortality of bariatric surgery on congestive heart failure in the USA: a nationwide analysis
Doctor S. Sinclair (Yankton, US)
Abstract Slides Video
Presentation thumbnail
What characterizes normotensive individuals with obesity and normal systolic heart function? A descriptive study from the SCAPIS cohort
Doctor J. Korduner (Lund, SE)
Abstract Slides Video
Presentation thumbnail
Effects of body mass index on worsening of heart failure and all-cause death in patients with heart failure and reduced left ventricular ejection fraction: a 10-year follow-up study
Mr M. Malmborg (Herlev, DK)
Abstract Slides Video
Presentation thumbnail
Association of epicardial adipose tissue with cardiac geometry alternation and diastolic dysfunction in the early stage of diabetic cardiomyopathy
Doctor J. Hsu (New Taipei City, TW)
Abstract Slides Video
Presentation thumbnail
Epicardial adipose tissue volume and density are associated with heart failure with improved ejection fraction
Doctor C. Yang (Shanghai, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Obesity and heart failure: what's new?

The Event

Event poster

ESC Congress 2024

1 September 2024 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Evaluation of tricuspid annular plane systolic excursion and epicardiac adipose tissue in patients with type 2 diabetes treated with oral semaglutide
thumbnail
Congress Presentation
The role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in epicardial adipose tissue modulation: a meta-analysis
thumbnail
Congress Presentation
Empagliflozin reduces extracellular volume and myocardial sodium content in patients with heart failure and preserved ejection fraction and correlates with reverse cardiac remodeling (EMPAG CMR-HF)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources